All Stories

  1. Forced oscillatory parameters as predictors of COPD assessment test improvement in untreated COPD patients
  2. Mucus Plugs and Small Airway Dysfunction in Asthma, COPD, and Asthma-COPD Overlap
  3. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients
  4. Benralizumab treatment may potentially restore the steroid sensitivity
  5. Oscillometry as a Predictor of Exercise Tolerance in COPD
  6. Benralizumab restored expression of key molecules involved in steroid-resistance in patients with severe asthma
  7. Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify asthma-COPD overlap
  8. Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease
  9. miRNA-15b-5p is a useful biomarker for asthma‐COPD overlap
  10. High fractional exhaled nitric oxide levels may predict short‐term worsening of respiratory oscillometry in asthma
  11. Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify Asthma-COPD overlap
  12. Forced Oscillatory Parameters Improved After Benralizumab Treatment in Severe Asthma
  13. Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma
  14. Annual changes in forced oscillation technique parameters correlate with FEV1 decline in patients with asthma, COPD, and asthma-COPD overlap
  15. Annual change in forced oscillation technique correlates with FEV1 decline in patients with asthma, COPD, and asthma-COPD overlap
  16. Effectiveness of benralizumab in patients with severe asthma
  17. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis
  18. Development of Stratified and Personalized Medicine Based on Pharmacogenomic and Pharmacokinetic Analyses
  21. Forced oscillation technique may identify severe asthma
  22. Forced oscillation technique may identify asthma-COPD overlap
  23. Forced Oscillation Technique May Identify Severe Asthma
  24. Improved cough- and sputum-related quality of life after initiation of treatment in pulmonary tuberculosis
  25. Impact of gene expression associated with glucocorticoid-induced transcript 1 (GLCCI1) on severe asthma and future exacerbation
  26. Comparison of the association between circulating vitamin D3 levels and clinical outcomes in patients with asthma and chronic obstructive pulmonary disease: a prospective observational study
  27. The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals
  28. Forced oscillatory parameters in reversibility testing as predictors for chronic cough responsive to ICS/LABA
  29. Accuracy of a nomogram for vancomycin in patients who are at risk for augmented renal clearance.
  30. Combined assessment of serum periostin and YKL-40 may identify ACO
  31. Time-Dependent Decline in Serum Phenytoin Concentration with Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese
  32. (CCTTT)n repeat polymorphism in NOS2 promoter influenced asthma exacerbation
  33. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy
  34. Association between pentanucleotide repeat polymorphism in NOS2 promoter and asthma exacerbations
  35. Comparable serum periostin levels among a Japanese population with asthma, COPD, and asthma-COPD overlap
  36. A clustering approach to identify the asthma-COPD overlap (ACO)
  37. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.
  38. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine
  39. Comparative Investigation of the Antiemetic Efficacy of Aprepitant Containing Antiemetic Regimen in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Combination Chemotherapy
  40. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients
  41. Febrile neutropenia is a risk factor for subtherapeutic concentrations of vancomycin (VCM).
  42. Usefulness of the forced oscillation technique in diagnosing asthma-COPD overlap syndrome
  43. Risk factors for hypernatremia in patients with tolvaptan treatment
  44. Febrile neutropenia in pediatric patients: a significant risk factor for augmented renal clearance
  45. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
  46. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy
  47. Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression
  48. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy
  49. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis
  50. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy
  51. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension
  52. Influence of CYP4F2 Polymorphisms and Plasma Vitamin K Levels on Warfarin Sensitivity in Japanese Pediatric Patients
  53. Antinociceptive Effects of St. John's Wort, Harpagophytum Procumbens Extract and Grape Seed Proanthocyanidins Extract in Mice